Daniel C. Adelman founded Sixal, Inc. Presently, he is Chief Medical Officer of Aimmune Therapeutics, Inc. Dr. Adelman is also on the board of Sixal, Inc. and Member of American Society of Hematology, Member of American Association for Cancer Research and Member of American Society of Clinical Oncology.

In the past Dr. Adelman held the position of Chief Medical Officer & Senior VP-Development at Sunesis Pharmaceuticals, Inc., Vice President-Clinical Operations & Biometric at Pharmacyclics LLC, Chief Medical Officer & Senior VP-Development at Alvine Pharmaceuticals, Inc., Clinical Scientist at Genentech, Inc. and Director-Clinical Allergy & Immunology at The University of California, San Francisco.

Daniel C. Adelman received an undergraduate degree from the University of California, Berkeley and a doctorate from the University of California, Davis.